Intas Science Imaging Instruments will launch the Dutch biotechnology company's NextGen PCR thermal cycler in the German market.
In a proof-of-concept study published in Nature Biotechnology this week, the team demonstrated that it could enzymatically synthesize 10-mer oligonucleotides.
Mayo Clinic researchers found that mutations in these genes could be found in nearly 6 percent of patients and argued for germline genetic testing for patients.
The assay detects a mutation that can confer hearing loss in patients, particularly neonates, who have taken gentamicin, an antibiotic prescribed for certain bacterial infections.
A combined assay to screen blood donations for HIV and hepatitis viruses and a test for West Nile virus are now cleared to run on the Procleix Panther system.
The Fusion module is an in-lab upgrade to Hologic's Panther instrument, which enables labs to extend the testing capabilities of their existing Panther.
Genome and RNA sequencing led to recurrent EGFR and BRAF rearrangements in cryptogenic congenital mesoblastic nephroma and infantile fibrosarcoma soft tumors.
With the California licensure, the company’s PCR-based Colvera colorectal cancer monitoring test is available in all US states except New York.
The funding totals up to $5.6 million over five years and will incorporate Talis' proprietary SlipChip technology.
The firm said that the decline was due to a customer shifting to internalizing genetic ordering, adverse weather, and the loss of an undisclosed commercial payor.
Researchers from Stanford University reported in a pilot study that seven RNA transcripts could predict preterm birth.
The collaboration will make use of Fluidigm's automated microfluidic systems to accelerate the design of panels for translational and clinical researchers.
As part of the collaboration, Texas A&M veterinarians will send canine urine samples to LexaGene for testing on its LX6 pathogen detection instrument.
The Dutch multinational is now on track to introduce a kitted version of the assay, which can be run on standard quantitative PCR equipment, by the end of the year.
Formerly known as NetBio, the firm is now the first to gain approval under the new standards of the Rapid DNA Act of 2017.
The test is Micronics’ first to receive FDA clearance, and the company is pursuing CE marking for it and the PanNAT system.
The companion diagnostic test identifies patients taking the Novartis drug Tasigna who are candidates for treatment-free remission monitoring.
The China FDA has approved Vela's cell-free DNA extraction kit, which can be coupled with RT-PCR or NGS workflows for further analysis.
The startup plans to launch research-use diagnostic tests this year and support customers wishing to build custom assays.
PavMed subsidiary Lucid will commercialize Case Western's EsoCheck technology to detect Barrett's esophagus, a precursor to esophageal cancer.
Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.
Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.
In Science this week: research regulation and reporting requirement reform, and more.
With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.